Stereotaxis announced that the first patients have been successfully treated using its Magnetic Interventional Ablation Catheter, MAGiC. Stereotaxis’ MAGiC catheter is a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures. The first human procedures using the MAGiC catheter were successfully performed by Prof. Germanas Marinskis and Assoc. Prof. Gediminas Rakauskas at Vilnius University Hospital Santaros Klinikos in Lithuania. Eight patients were treated in the first week of January, following receipt of approvals to begin enrollment in the prospective clinical trial. Data from the clinical trial will support the CE Mark submission of MAGiC. “This is a significant milestone for Stereotaxis as we advance our comprehensive innovation strategy,” said David Fischel, Stereotaxis Chairman and CEO. “We look forward to the impact MAGiC, a key pillar in our new product ecosystem, will have on patients, physicians, and the advancement of medicine.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on STXS:
- Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter
- Stereotaxis announces first patients treated using Genesis RMN System
- Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients
- Stereotaxis to Participate in Piper Sandler 35th Annual Healthcare Conference
- Stereotaxis price target lowered to $4 from $4.50 at B. Riley
Questions or Comments about the article? Write to editor@tipranks.com